The limited availability of ALK1-mutated HMVECs prompted us to additionally include HMVECs from 3 PAH patients with more frequent heterozygous mutations in the type II BMP9/10 receptor BMPR2, for validation of target genes by RT-qPCR. This evidence concerns the gene GDF2 and pulmonary arterial hypertension.